Literature DB >> 6903579

Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein.

M R Daha, L A van Es.   

Abstract

The sera of some patients with SLE contain an IgG antibody (F-42) directed against the classical pathway C3 convertase (C-42), which is capable of stabilizing C42 in a dose-dependent manner. The half-life (T 1/2) of C42 is prolonged by F-42. In order to determine whether C4-binding protein was capable of reversing stabilization of C42, stabilized and unstabilized cell-bound C42 were exposed to purified C4-bp and the convertase activity was assessed. C4-bp was capable of accelerating the decay of C42 in a dose-dependent manner; 2 microgram/ml C4-bp reduced the T 1/2 of C42 from 5 to 2.5 min at 30 degrees C. On the other hand, 16 microgram C4-bp could reverse stabilization of C42 by F-42 from T 1/2 = 78 min to a T 1/2 - 40 min; 128 microgram C4-bp reduced the T 1/2 of stabilized C42 to 4 min. Functional inactivation of C42 occurs via enhanced decay-dissociation of C2 from the convertase by C4-bp, as shown by the release of 125I-C2i from the cell-bound convertase. Stabilization of C42 by F-42 is caused by prevention of decay-dissociation of 125I-C2. F-42 was also capable of stabilizing C4oxy2 even further, as shown by prolongation of the T 1/2 of cell-bound C4 oxy2 to a T 1/2 of at least 300 min at 30 degrees C.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6903579

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  C4b-binding protein, a regulatory protein of complement.

Authors:  S R Barnum
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 2.  The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system.

Authors:  M Hessing
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

3.  A novel method for direct measurement of complement convertases activity in human serum.

Authors:  A M Blom; E B Volokhina; V Fransson; P Strömberg; L Berghard; M Viktorelius; T E Mollnes; M López-Trascasa; L P van den Heuvel; T H Goodship; K J Marchbank; M Okroj
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 4.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

5.  Complement regulator C4BP binds to Staphylococcus aureus surface proteins SdrE and Bbp inhibiting bacterial opsonization and killing.

Authors:  Pamela S Hair; Caitlin K Foley; Neel K Krishna; Julius O Nyalwidhe; Joan A Geoghegan; Timothy J Foster; Kenji M Cunnion
Journal:  Results Immunol       Date:  2013-11-09

6.  Modulation of classical C3 convertase of complement by tear lactoferrin.

Authors:  A Kijlstra; S H Jeurissen
Journal:  Immunology       Date:  1982-10       Impact factor: 7.397

7.  C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.

Authors:  Y Tanuma; H Ohi; S Watanabe; M Seki; M Hatano
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

8.  Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A van Es
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

9.  Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; J Hermans; L A van Es; A Cats
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

10.  Regulation of immune complex-mediated complement activation by autoantibodies (F-42) isolated from sera of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A Vanes
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.